BioSpace News Archive

Incyte and Syndax Pharmaceuticals announced the full results from the pivotal Phase 2 AGAVE-201 trial of axatilimab, an anti-CSF-1R antibody, in adult and pediatric patients with refractory chronic graft-versus-host disease who had received at least two prior lines of systemic therapy.

Astellas Pharma Inc. announced the European Commission on December 7 approved VEOZATM 45 mg once daily for the treatment of moderate to severe vasomotor symptoms associated with menopause.

Antengene Corporation Limited announced that the first patient has been dosed in the Phase I PERFORM trial of ATG-031 for the treatment of patients with advanced solid tumors or B-cell non-Hodgkin’s lymphoma, at The University of Texas MD Anderson Cancer Center, the lead center of the study that also includes three other clinical trial centers across the U.S.

Innate Pharma SA announced positive final results from the Phase 2 TELLOMAK study in Sézary Syndrome.

Dizal presented the full analysis of the multinational pivotal study of golidocitinib for r/r PTCL in an oral presentation at the 65th American Society of Hematology Annual Meeting and Exposition.

Research findings being presented at the 65th American Society of Hematology Annual Meeting and Exposition highlight new treatment approaches that are enabling patients to live longer or better, judicious uses of older treatment approaches, and how a powerful, relatively new prognostic tool is helping identify patients who are more or less likely to benefit from both older and newer treatments.

Vincerx Pharma, Inc. announced the presentation of two preclinical posters at the 65th Annual Meeting of the American Society for Hematology for VIP943, for leukemias and myelodysplastic syndrome, and VIP924, for B-cell malignancies.

Poseida Therapeutics, Inc. announced early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted allogeneic, T stem cell memory -rich chimeric antigen receptor -T therapy candidate.

Updated data from bluebird bio inc.’s gene therapy program in transfusion-dependent beta-thalassemia were presented at the 65th American Society of Hematology Annual Meeting & Exposition.

GlycoMimetics, Inc. announced the 65th American Society of Hematology Annual Meeting will feature two presentations on uproleselan, including an investigator-initiated trial studying the first-in-class E-selectin antagonist in patients with treated secondary Acute Myeloid Leukemia.